ATLANTA (MedPage Today) -- An oral drug called ibrutinib targeting Bruton's tyrosine kinase in chronic lymphocytic leukemia (CLL) showed excellent efficacy and safety in two phase II trials, researchers said here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment